CALT - Calliditas Therapeutics Revenue Growth YoY (Last 12 Months)

Graphic logo of calliditas.se (CALT)

Calliditas Therapeutics (CALT) minimizes risks by focusing on therapies for rare nephrological pathologies with high demand. The GURU.Markets platform reflects the year-over-year sales trajectory (TTM), where the 178.60 indicator determines the metric's magnitude. Calliditas Therapeutics is striving for the expansion of the drug Tarpeyo to capture market share, while support from a European behemoth and a 100% patient retention rate strengthen its regulatory status.

CALT Calliditas: Sales Growth YoY (Last Twelve Months) in the range 02/11/2024 - 02/20/2024

calliditas.se (CALT) - metric breakdowns and financial figures

- market value and analyst target forecast:
Summary company analytics:calliditas.se - CALT
Manufactured products of Calliditas Therapeutics

This indicator measures the rolling revenue growth rate over the last 12 months, allowing for the capture of real-time market shifts prior to the publication of official reports. By analyzing year-over-year sales growth (TTM), an investor assesses the effectiveness of Calliditas Therapeutics (CALT) expansion into new markets and the successful implementation of rare kidney disease therapies supported by insurance companies.